Analysts Set Arvinas, Inc. (NASDAQ:ARVN) PT at $34.33

Arvinas, Inc. (NASDAQ:ARVN) has been assigned an average rating of “Moderate Buy” from the nineteen brokerages that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $25.82.

ARVN has been the topic of a number of recent research reports. Citigroup lowered their target price on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, March 7th. HC Wainwright dropped their target price on shares of Arvinas from $81.00 to $24.00 and set a “buy” rating for the company in a research report on Friday. Wedbush cut Arvinas from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $57.00 to $12.00 in a report on Wednesday, March 12th. Stifel Nicolaus dropped their price objective on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Finally, Truist Financial cut their price target on Arvinas from $65.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th.

Insider Buying and Selling

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now directly owns 110,023 shares of the company’s stock, valued at approximately $945,097.57. The trade was a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 over the last 90 days. Company insiders own 5.23% of the company’s stock.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its holdings in Arvinas by 1.6% during the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock worth $714,000 after purchasing an additional 581 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Arvinas by 0.9% during the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock valued at $1,685,000 after buying an additional 754 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Arvinas by 0.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock valued at $2,694,000 after acquiring an additional 777 shares during the period. Bank of Montreal Can lifted its holdings in Arvinas by 2.7% during the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock worth $755,000 after purchasing an additional 1,044 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares in the last quarter. 95.19% of the stock is owned by institutional investors.

Arvinas Trading Up 6.8 %

NASDAQ:ARVN opened at $7.72 on Thursday. The stock has a market capitalization of $563.49 million, a PE ratio of -2.79 and a beta of 2.21. The firm has a fifty day simple moving average of $9.66 and a 200 day simple moving average of $17.44. Arvinas has a 1-year low of $5.94 and a 1-year high of $37.38.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. Arvinas’s revenue was up 646.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.97) EPS. On average, equities analysts predict that Arvinas will post -3.81 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.